Skip to main content
SpringerLink
Log in

Outcome Measures in Psoriasis and Atopic Eczema

  • Chapter
  • First Online:
Biologic and Systemic Agents in Dermatology

Abstract

There are many new and emerging therapies for complex skin disorders such as psoriasis and atopic dermatitis. In order to measure disease severity and effect of therapy, valid outcome measures are commonly employed in clinical trials and in clinical practice. The most commonly used in psoriasis clinical trials include the Psoriasis Area and Severity Index (PASI), the extent of body surface area involvement (BSA), and various physician or investigator global assessments (PGA or IGA). Measures are also available to assess nail, palmar-plantar, scalp psoriasis, and target lesions. In eczema/atopic dermatitis studies, important measures include the Eczema Area and Severity Index (EASI), the SCORAD, and the IGA. This chapter focuses on the most commonly used and the most psychometrically valid efficacy measures in clinical trials for psoriasis and eczema.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Institutional subscriptions

References

  1. Kirwan JR, Chaput de Saintonge DM, Joyce CR. Clinical judgment analysis. Q J Med. 1990;76(281):935–49.

    CAS  PubMed  Google Scholar 

  2. Boers M, Brooks P, Strand CV, Tugwell P. The OMERACT filter for outcome measures in rheumatology. J Rheumatol. 1998;25(2):198–9.

    CAS  PubMed  Google Scholar 

  3. Kirwan JR, Boers M, Tugwell P. Updating the OMERACT filter at OMERACT 11. J Rheumatol. 2014;41(5):975–7.

    Article  PubMed  Google Scholar 

  4. Chalmers JR, Simpson E, Apfelbacher CJ, Thomas KS, von Kobyletzki L, Schmitt J, et al. Report from the fourth international consensus meeting to harmonize core outcome measures for atopic eczema/dermatitis clinical trials (HOME initiative). Br J Dermatol. 2016;175(1):69–79.

    Article  CAS  PubMed  Google Scholar 

  5. Naldi L, Svensson A, Diepgen T, Elsner P, Grob JJ, Coenraads PJ, et al. Randomized clinical trials for psoriasis 1977–2000: the EDEN survey. J Invest Dermatol. 2003;120(5):738–41.

    Article  CAS  PubMed  Google Scholar 

  6. Fredriksson T, Pettersson U. Severe psoriasis—oral therapy with a new retinoid. Dermatologica. 1978;157(4):238–44.

    Article  CAS  PubMed  Google Scholar 

  7. Marks R, Barton SP, Shuttleworth D, Finlay AY. Assessment of disease progress in psoriasis. Arch Dermatol. 1989;125(2):235–40.

    Article  CAS  PubMed  Google Scholar 

  8. Manalo IF, Gilbert KE, Wu JJ. An updated survey for the 2007–2013 period of randomized controlled trials for psoriasis: treatment modalities, study designs, comparators, outcome measures and sponsorship. J Eur Acad Dermatol Venereol. 2015;29(10):1945–50.

    Article  CAS  PubMed  Google Scholar 

  9. Puzenat E, Bronsard V, Prey S, Gourraud PA, Aractingi S, Bagot M, et al. What are the best outcome measures for assessing plaque psoriasis severity? A systematic review of the literature. J Eur Acad Dermatol Venereol. 2010;24(Suppl 2):10–6.

    Article  PubMed  Google Scholar 

  10. Spuls PI, Lecluse LL, Poulsen ML, Bos JD, Stern RS, Nijsten T. How good are clinical severity and outcome measures for psoriasis?: quantitative evaluation in a systematic review. J Invest Dermatol. 2010;130(4):933–43.

    Article  CAS  PubMed  Google Scholar 

  11. Berth-Jones J, Grotzinger K, Rainville C, Pham B, Huang J, Daly S, et al. A study examining inter- and intrarater reliability of three scales for measuring severity of psoriasis: psoriasis area and severity index, physician’s global assessment and lattice system physician’s global assessment. Br J Dermatol. 2006;155(4):707–13.

    Article  CAS  PubMed  Google Scholar 

  12. Thaci D, Blauvelt A, Reich K, Tsai TF, Vanaclocha F, Kingo K, et al. Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial. J Am Acad Dermatol. 2015;73(3):400–9.

    Article  CAS  PubMed  Google Scholar 

  13. Carlin CS, Feldman SR, Krueger JG, Menter A, Krueger GG. A 50% reduction in the psoriasis area and severity index (PASI 50) is a clinically significant endpoint in the assessment of psoriasis. J Am Acad Dermatol. 2004;50(6):859–66.

    Article  PubMed  Google Scholar 

  14. Gottlieb AB, Krueger JG, Wittkowski K, Dedrick R, Walicke PA, Garovoy M. Psoriasis as a model for T-cell-mediated disease: immunobiologic and clinical effects of treatment with multiple doses of efalizumab, an anti-CD11a antibody. Arch Dermatol. 2002;138(5):591–600.

    Article  CAS  PubMed  Google Scholar 

  15. Krueger GG, Papp KA, Stough DB, Loven KH, Gulliver WP, Ellis CN, et al. A randomized, double-blind, placebo-controlled phase III study evaluating efficacy and tolerability of 2 courses of alefacept in patients with chronic plaque psoriasis. J Am Acad Dermatol. 2002;47(6):821–33.

    Article  PubMed  Google Scholar 

  16. Edson-Heredia E, Banerjee S, Zhu B, Maeda-Chubachi T, Cameron GS, Shen W, et al. A high level of clinical response is associated with improved patient-reported outcomes in psoriasis: analyses from a phase 2 study in patients treated with ixekizumab. J Eur Acad Dermatol Venereol. 2016;30(5):864–5.

    Article  CAS  PubMed  Google Scholar 

  17. Robinson A, Kardos M, Kimball AB. Physician global assessment (PGA) and psoriasis area and severity index (PASI): why do both? A systematic analysis of randomized controlled trials of biologic agents for moderate to severe plaque psoriasis. J Am Acad Dermatol. 2012;66(3):369–75.

    Article  PubMed  Google Scholar 

  18. Walsh JA, McFadden M, Woodcock J, Clegg DO, Helliwell P, Dommasch E, et al. Product of the physician global assessment and body surface area: a simple static measure of psoriasis severity in a longitudinal cohort. J Am Acad Dermatol. 2013;69(6):931–7.

    Article  PubMed  Google Scholar 

  19. Cappelleri JC, Bushmakin AG, Harness J, Mamolo C. Psychometric validation of the physician global assessment scale for assessing severity of psoriasis disease activity. Qual Life Res. 2013;22(9):2489–99.

    Article  CAS  PubMed  Google Scholar 

  20. Langley RG, Ellis CN. Evaluating psoriasis with psoriasis area and severity index, psoriasis global assessment, and lattice system physician’s global assessment. J Am Acad Dermatol. 2004;51(4):563–9.

    Article  PubMed  Google Scholar 

  21. Ports WC, Khan S, Lan S, Lamba M, Bolduc C, Bissonnette R, et al. A randomized phase 2a efficacy and safety trial of the topical Janus kinase inhibitor tofacitinib in the treatment of chronic plaque psoriasis. Br J Dermatol. 2013;169(1):137–45.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Boy MG, Wang C, Wilkinson BE, Chow VF, Clucas AT, Krueger JG, et al. Double-blind, placebo-controlled, dose-escalation study to evaluate the pharmacologic effect of CP-690,550 in patients with psoriasis. J Invest Dermatol. 2009;129(9):2299–302.

    Article  CAS  PubMed  Google Scholar 

  23. Czarnowicki T, Linkner RV, Suarez-Farinas M, Ingber A, Lebwohl M. An investigator-initiated, double-blind, vehicle-controlled pilot study: assessment for tachyphylaxis to topically occluded halobetasol 0.05% ointment in the treatment of psoriasis. J Am Acad Dermatol. 2014;71(5):954–9. e1

    Article  CAS  PubMed  Google Scholar 

  24. Dommasch E, Walsh, J.W., Woodcock, J.A., Shin, D., Callis Duffin, K., Gelfand J. Validity of the simple measure for assessing psoriasis activity (S-MAPA). World Congress of Dermatology, Seoul, Korea: 2011 May 24-29, 2011. Report No.

    Google Scholar 

  25. Strober BE, Sobell JM, Duffin KC, Bao Y, Guerin A, Yang H, et al. Sleep quality and other patient-reported outcomes improve after patients with psoriasis with suboptimal response to other systemic therapies are switched to adalimumab: results from PROGRESS, an open-label Phase IIIB trial. Br J Dermatol. 2012;167(6):1374–81.

    Article  CAS  PubMed  Google Scholar 

  26. Wallace AB. The exposure treatment of burns. Lancet. 1951;1(6653):501–4.

    Article  CAS  PubMed  Google Scholar 

  27. Hettiaratchy S, Papini R. Initial management of a major burn: II—assessment and resuscitation. BMJ. 2004;329(7457):101–3.

    Article  PubMed  PubMed Central  Google Scholar 

  28. Long CC, Finlay AY, Averill RW. The rule of hand: 4 hand areas = 2 FTU = 1 g. Arch Dermatol. 1992;128(8):1129–30.

    Article  CAS  PubMed  Google Scholar 

  29. Rossiter ND, Chapman P, Haywood IA. How big is a hand? Burns. 1996;22(3):230–1.

    Article  CAS  PubMed  Google Scholar 

  30. Nagel TR, Schunk JE. Using the hand to estimate the surface area of a burn in children. Pediatr Emerg Care. 1997;13(4):254–5.

    Article  CAS  PubMed  Google Scholar 

  31. Ramsay B, Lawrence CM. Measurement of involved surface area in patients with psoriasis. Br J Dermatol. 1991;124(6):565–70.

    Article  CAS  PubMed  Google Scholar 

  32. Ashcroft DM, Wan Po AL, Williams HC, Griffiths CE. Clinical measures of disease severity and outcome in psoriasis: a critical appraisal of their quality. Br J Dermatol. 1999;141(2):185–91.

    Article  CAS  PubMed  Google Scholar 

  33. Armstrong AW, Siegel MP, Bagel J, Boh EE, Buell M, Cooper KD, et al. From the medical board of the national psoriasis foundation: treatment targets for plaque psoriasis. J Am Acad Dermatol. 2017;76(2):290–8.

    Article  PubMed  Google Scholar 

  34. Takahashi MD, Chouela EN, Dorantes GL, Roselino AM, Santamaria J, Allevato MA, et al. Efalizumab in the treatment of scalp, palmoplantar and nail psoriasis: results of a 24-week Latin American Study. Arch Drug Inf. 2010;3(1):1–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  35. Bagel J, Lynde C, Tyring S, Kricorian G, Shi Y, Klekotka P. Moderate to severe plaque psoriasis with scalp involvement: a randomized, double-blind, placebo-controlled study of etanercept. J Am Acad Dermatol. 2012;67(1):86–92.

    Article  PubMed  Google Scholar 

  36. Reich K, Leonardi C, Lebwohl M, Kerdel F, Okubo Y, Romiti R, et al. Sustained response with ixekizumab treatment of moderate-to-severe psoriasis with scalp involvement: results from three phase 3 trials (UNCOVER-1, UNCOVER-2, UNCOVER-3). J Dermatolog Treat. 2017;28(4):282–7.

    Article  CAS  PubMed  Google Scholar 

  37. Thaci D, Daiber W, Boehncke WH, Kaufmann R. Calcipotriol solution for the treatment of scalp psoriasis: evaluation of efficacy, safety and acceptance in 3,396 patients. Dermatology. 2001;203(2):153–6.

    Article  CAS  PubMed  Google Scholar 

  38. Cassell SE, Bieber JD, Rich P, Tutuncu ZN, Lee SJ, Kalunian KC, et al. The modified nail psoriasis severity index: validation of an instrument to assess psoriatic nail involvement in patients with psoriatic arthritis. J Rheumatol. 2007;34(1):123–9.

    PubMed  Google Scholar 

  39. Rich P, Scher RK. Nail psoriasis severity index: a useful tool for evaluation of nail psoriasis. J Am Acad Dermatol. 2003;49(2):206–12.

    Article  PubMed  Google Scholar 

  40. Augustin M, Blome C, Costanzo A, Dauden E, Ferrandiz C, Girolomoni G, et al. Nail assessment in psoriasis and psoriatic arthritis (NAPPA): development and validation of a tool for assessment of nail psoriasis outcomes. Br J Dermatol. 2014;170(3):591–8.

    Article  CAS  PubMed  Google Scholar 

  41. Parrish CA, Sobera JO, Elewski BE. Modification of the nail psoriasis severity index. J Am Acad Dermatol. 2005;53(4):745–6. author reply 6-7

    Article  PubMed  Google Scholar 

  42. Aktan S, Ilknur T, Akin C, Ozkan S. Interobserver reliability of the nail psoriasis severity index. Clin Exp Dermatol. 2007;32(2):141–4.

    Article  CAS  PubMed  Google Scholar 

  43. van der Velden HM, Klaassen KM, van de Kerkhof PC, Pasch MC. Invited reply to “possible reconsideration of the nail psoriasis severity index (NAPSI) score”. J Am Acad Dermatol. 2013;69(6):1054.

    Article  PubMed  Google Scholar 

  44. Finlay AY, Khan GK. Dermatology life quality index (DLQI)—a simple practical measure for routine clinical use. Clin Exp Dermatol. 1994;19(3):210–6.

    Article  CAS  PubMed  Google Scholar 

  45. Lewis V, Finlay AY. 10 years experience of the dermatology life quality index (DLQI). J Investig Dermatol Symp Proc. 2004;9(2):169–80.

    Article  PubMed  Google Scholar 

  46. Basra MK, Salek MS, Camilleri L, Sturkey R, Finlay AY. Determining the minimal clinically important difference and responsiveness of the dermatology life quality index (DLQI): further data. Dermatology. 2015;230(1):27–33.

    Article  CAS  PubMed  Google Scholar 

  47. Mrowietz U, Kragballe K, Reich K, Spuls P, Griffiths CE, Nast A, et al. Definition of treatment goals for moderate to severe psoriasis: a European consensus. Arch Dermatol Res. 2011;303(1):1–10.

    Article  CAS  PubMed  Google Scholar 

  48. Nijsten T. Dermatology life quality index: time to move forward. J Invest Dermatol. 2012;132(1):11–3.

    Article  CAS  PubMed  Google Scholar 

  49. Mease PJ, Gladman DD, Papp KA, Khraishi MM, Thaci D, Behrens F, et al. Prevalence of rheumatologist-diagnosed psoriatic arthritis in patients with psoriasis in European/North American dermatology clinics. J Am Acad Dermatol. 2013;69(5):729–35.

    Article  PubMed  Google Scholar 

  50. Mease PJ. Measures of psoriatic arthritis: tender and Swollen Joint Assessment, Psoriasis Area and Severity Index (PASI), Nail Psoriasis Severity Index (NAPSI), Modified Nail Psoriasis Severity Index (mNAPSI), Mander/Newcastle Enthesitis Index (MEI), Leeds Enthesitis Index (LEI), Spondyloarthritis Research Consortium of Canada (SPARCC), Maastricht Ankylosing Spondylitis Enthesis Score (MASES), Leeds Dactylitis Index (LDI), Patient Global for Psoriatic Arthritis, Dermatology Life Quality Index (DLQI), Psoriatic Arthritis Quality of Life (PsAQOL), Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F), Psoriatic Arthritis Response Criteria (PsARC), Psoriatic Arthritis Joint Activity Index (PsAJAI), Disease Activity in Psoriatic Arthritis (DAPSA), and Composite Psoriatic Disease Activity Index (CPDAI). Arthritis Care Res (Hoboken). 2011;63(Suppl 11):S64–85.

    Article  Google Scholar 

  51. Felson DT, Anderson JJ, Boers M, Bombardier C, Furst D, Goldsmith C, et al. American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum. 1995;38(6):727–35.

    Article  CAS  PubMed  Google Scholar 

  52. Callis Duffin K, Mease PJ. Psoriasis and psoriatic arthritis video project 2010: a report from the GRAPPA annual meeting. J Rheumatol. 2011;38(3):562–3.

    Article  PubMed  Google Scholar 

  53. Callis Duffin K, Armstrong AW, Mease PJ. Psoriasis and psoriatic arthritis video project: an update from the GRAPPA 2011 annual meeting. J Rheumatol. 2012;39(11):2198–200.

    Article  PubMed  Google Scholar 

  54. Callis Duffin K, Armstrong AW, Mease PJ. Psoriasis and psoriatic arthritis video project: an update from the 2012 GRAPPA annual meeting. J Rheumatol. 2013;40(8):1455–6.

    Article  PubMed  Google Scholar 

  55. Callis Duffin K, Gottlieb AB. Outcome measures for psoriasis severity: a report from the GRAPPA 2012 annual meeting. J Rheumatol. 2013;40(8):1423–4.

    Article  PubMed  Google Scholar 

  56. Mease PJ, Helliwell PS, Boehncke WH, Coates LC, FitzGerald O, Gladman DD, et al. GRAPPA 2015 research and education project reports. J Rheumatol. 2016;43(5):979–85.

    Article  PubMed  Google Scholar 

  57. Armstrong AW, Parsi K, Schupp CW, Mease PJ, Duffin KC. Standardizing training for psoriasis measures: effectiveness of an online training video on psoriasis area and severity index assessment by physician and patient raters. JAMA Dermatol. 2013;149(5):577–82.

    Article  PubMed  Google Scholar 

  58. Schmitt J, Langan S, Williams HC, European Dermato-Epidemiology N. What are the best outcome measurements for atopic eczema? A systematic review. J Allergy Clin Immunol. 2007;120(6):1389–98.

    Article  PubMed  Google Scholar 

  59. Chalmers JR, Schmitt J, Apfelbacher C, Dohil M, Eichenfield LF, Simpson EL, et al. Report from the third international consensus meeting to harmonise core outcome measures for atopic eczema/dermatitis clinical trials (HOME). Br J Dermatol. 2014;171(6):1318–25.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  60. Schmitt J, Apfelbacher C, Spuls PI, Thomas KS, Simpson EL, Furue M, et al. The harmonizing outcome measures for eczema (HOME) roadmap: a methodological framework to develop core sets of outcome measurements in dermatology. J Invest Dermatol. 2015;135(1):24–30.

    Article  CAS  PubMed  Google Scholar 

  61. Spuls PI, Gerbens LAA, Simpson E, Apfelbacher CJ, Chalmers JR, Thomas KS, et al. Patient-oriented eczema measure (POEM), a core instrument to measure symptoms in clinical trials: a harmonising outcome measures for eczema (HOME) statement. Br J Dermatol. 2017;176(4):979–84.

    Article  CAS  PubMed  Google Scholar 

  62. Hanifin JM, Thurston M, Omoto M, Cherill R, Tofte SJ, Graeber M. The eczema area and severity index (EASI): assessment of reliability in atopic dermatitis. EASI Evaluator Group. Exp Dermatol. 2001;10(1):11–8.

    Article  CAS  PubMed  Google Scholar 

  63. Simpson EL, Bieber T, Guttman-Yassky E, Beck LA, Blauvelt A, Cork MJ, et al. Two phase 3 trials of dupilumab versus placebo in atopic dermatitis. N Engl J Med. 2016;375(24):2335–48.

    Article  CAS  PubMed  Google Scholar 

  64. Leshem YA, Hajar T, Hanifin JM, Simpson EL. What the eczema area and severity index score tells us about the severity of atopic dermatitis: an interpretability study. Br J Dermatol. 2015;172(5):1353–7.

    Article  CAS  PubMed  Google Scholar 

  65. Consensus Report of the European Task Force on Atopic Dermatitis. Severity scoring of atopic dermatitis: the SCORAD index. Dermatology. 1993;186(1):23–31.

    Article  Google Scholar 

  66. Schram ME, Spuls PI, Leeflang MM, Lindeboom R, Bos JD, Schmitt J. EASI, (objective) SCORAD and POEM for atopic eczema: responsiveness and minimal clinically important difference. Allergy. 2012;67(1):99–106.

    Article  CAS  PubMed  Google Scholar 

  67. Futamura M, Leshem YA, Thomas KS, Nankervis H, Williams HC, Simpson EL. A systematic review of investigator global assessment (IGA) in atopic dermatitis (AD) trials: many options, no standards. J Am Acad Dermatol. 2016;74(2):288–94.

    Article  PubMed  Google Scholar 

  68. Charman CR, Venn AJ, Williams HC. The patient-oriented eczema measure: development and initial validation of a new tool for measuring atopic eczema severity from the patients' perspective. Arch Dermatol. 2004;140(12):1513–9.

    Article  PubMed  Google Scholar 

  69. Charman CR, Venn AJ, Ravenscroft JC, Williams HC. Translating patient-oriented eczema measure (POEM) scores into clinical practice by suggesting severity strata derived using anchor-based methods. Br J Dermatol. 2013;169(6):1326–32.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  70. Bushnell DM, Martin ML, McCarrier K, Gordon K, Chiou CF, Huang X, et al. Validation of the psoriasis symptom inventory (PSI), a patient-reported outcome measure to assess psoriasis symptom severity. J Dermatolog Treat. 2013;24(5):356–60.

    Article  PubMed  Google Scholar 

  71. Bushnell DM, Martin ML, Scanlon M, Chen T, Chau D, Viswanathan HN. Equivalence and measurement properties of an electronic version of the psoriasis symptom inventory. Qual Life Res. 2014;23(3):897–906.

    Article  PubMed  Google Scholar 

  72. Gordon KB, Kimball AB, Chau D, Viswanathan HN, Li J, Revicki DA, et al. Impact of brodalumab treatment on psoriasis symptoms and health-related quality of life: use of a novel patient-reported outcome measure, the psoriasis symptom inventory. Br J Dermatol. 2014;170(3):705–15.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  73. Revicki DA, Jin Y, Wilson HD, Chau D, Viswanathan HN. Reliability and validity of the psoriasis symptom inventory in patients with moderate-to-severe psoriasis. J Dermatolog Treat. 2014;25(1):8–14.

    Article  CAS  PubMed  Google Scholar 

  74. Strober B, Sigurgeirsson B, Popp G, Sinclair R, Krell J, Stonkus S, et al. Secukinumab improves patient-reported psoriasis symptoms of itching, pain, and scaling: results of two phase 3, randomized, placebo-controlled clinical trials. Int J Dermatol. 2016;55(4):401–7.

    Article  CAS  PubMed  Google Scholar 

  75. Strober BE, Nyirady J, Mallya UG, Guettner A, Papavassilis C, Gottlieb AB, et al. Item-level psychometric properties for a new patient-reported psoriasis symptom diary. Value Health. 2013;16(6):1014–22.

    Article  PubMed  Google Scholar 

  76. van Riel P, van Gestel A, Scott D. EULAR handbook of clinical assessment in rheumatoid arthritis. The Netherlands: Van Zuiden Communications B.V.; 2000.

    Google Scholar 

  77. Helliwell PS, Firth J, Ibrahim GH, Melsom RD, Shah I, Turner DE. Development of an assessment tool for dactylitis in patients with psoriatic arthritis. J Rheumatol. 2005;32(9):1745–50.

    PubMed  Google Scholar 

  78. Healy PJ, Helliwell PS. Measuring clinical enthesitis in psoriatic arthritis: assessment of existing measures and development of an instrument specific to psoriatic arthritis. Arthritis Rheum. 2008;59(5):686–91.

    Article  PubMed  Google Scholar 

  79. Maksymowych WP, Mallon C, Morrow S, Shojania K, Olszynski WP, Wong RL, et al. Development and validation of the spondyloarthritis research consortium of Canada (SPARCC) enthesitis index. Ann Rheum Dis. 2009;68(6):948–53.

    Article  CAS  PubMed  Google Scholar 

  80. van Gestel AM, Prevoo ML, van 't Hof MA, van Rijswijk MH, van de Putte LB, van Riel PL. Development and validation of the European league against rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumatism Criteria. Arthritis Rheum. 1996;39(1):34–40.

    Article  PubMed  Google Scholar 

  81. Schoels M, Aletaha D, Funovits J, Kavanaugh A, Baker D, Smolen JS. Application of the DAREA/DAPSA score for assessment of disease activity in psoriatic arthritis. Ann Rheum Dis. 2010;69(8):1441–7.

    Article  PubMed  Google Scholar 

  82. Mumtaz A, Gallagher P, Kirby B, Waxman R, Coates LC, Veale JD, et al. Development of a preliminary composite disease activity index in psoriatic arthritis. Ann Rheum Dis. 2011;70(2):272–7.

    Article  PubMed  Google Scholar 

  83. Helliwell PS, FitzGerald O, Fransen J, Gladman DD, Kreuger GG, Callis-Duffin K, et al. The development of candidate composite disease activity and responder indices for psoriatic arthritis (GRACE project). Ann Rheum Dis. 2013;72(6):986–91.

    Article  PubMed  Google Scholar 

  84. Eichenfield LF, Lucky AW, Boguniewicz M, Langley RG, Cherill R, Marshall K, et al. Safety and efficacy of pimecrolimus (ASM 981) cream 1% in the treatment of mild and moderate atopic dermatitis in children and adolescents. J Am Acad Dermatol. 2002;46(4):495–504.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Dermatology, University of Utah, Salt Lake City, UT, USA

    Kristina Callis Duffin MD, MS

Authors
  1. Kristina Callis Duffin MD, MS
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Kristina Callis Duffin MD, MS .

Editor information

Editors and Affiliations

  1. Division of Dermatology, David Geffen School of Medicine a UCLA, Los Angeles, California, USA

    Paul S. Yamauchi

Rights and permissions

Reprints and permissions

Copyright information

© 2018 Springer International Publishing AG

About this chapter

Cite this chapter

Duffin, K.C. (2018). Outcome Measures in Psoriasis and Atopic Eczema. In: Yamauchi, P. (eds) Biologic and Systemic Agents in Dermatology. Springer, Cham. https://doi.org/10.1007/978-3-319-66884-0_2

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-66884-0_2

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-66883-3

  • Online ISBN: 978-3-319-66884-0

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation